Human Bocavirus in Children

To the Editor: Respiratory tract infection is a major cause of illness in children. Despite the availability of sensitive diagnostic methods, detecting infectious agents is difficult in a substantial proportion of respiratory samples from children with respiratory tract disease (1). This fact suggests the existence of currently unknown respiratory pathogens.

A new virus has been recently identified in respiratory samples from children with lower respiratory tract disease in Sweden (2). Analysis of the full-length genome sequence showed that this virus is closely related to bovine parvovirus and canine minute virus and is a member of the genus Bocavirus, subfamily Parvovirinae. This virus has been provisionally named human Bocavirus (HBoV) (2). HBoV in respiratory samples from Australian children was also recently reported (3). Involvement of this new virus in respiratory tract diseases merits further investigation. We have therefore retrospectively tested for HBoV nasopharyngeal samples collected from children <5 years of age hospitalized with respiratory tract disease.

Samples were collected from 262 children from November 1, 2003, to January 31, 2004. The samples were tested for respiratory viruses by using direct immunofluorescence assays with monoclonal antibodies to respiratory syncytial virus; influenza virus types A and B; parainfluenza virus types 1, 2, and 3; and adenovirus. Samples were also placed on MRC5 cell monolayers for virus isolation and tested for human metapneumovirus by reverse transcription–polymerase chain reaction (RT-PCR). Nucleic acids were extracted from samples, stored at –80°C, and tested for HBoV DNA by PCR with primers specific for the predicted NP1 gene as previously described (2). The expected product size was 354 bp. In each experiment, a negative control was included, and positive samples were confirmed by analyzing a second sample. Amplification specificity was verified by sequencing.

Nine (3.4%) samples were positive. Comparison of PCR product sequences of these 9 isolates (GenBank accession nos. AM109958–AM109966) showed minor differences that occurred at 1 to 4 nucleotide positions, and a high level of sequence identity (99%–100%) was observed with the NP1 sequences of the previously identified ST1 and ST2 isolates (2). This finding indicates that HBoV is a highly conserved virus.

HBoV was the only virus identified in 6 children and was associated with respiratory syncytial virus in 3 other children. An infection with other respiratory viruses was detected among 153 (60.5%) of the 253 HBoV-negative children. The viruses identified were respiratory syncytial virus in 114 (43.5%) samples, human metapneumovirus in 27 (10.3%) samples, influenza A virus in 14 (5.4%) samples, rhinovirus in 4 (1.5%) samples, adenovirus in 2 (0.8%) samples, and parainfluenza virus type 3 in 1 (0.4%) sample. Respiratory syncytial virus was associated with human metapneumovirus in 9 (3.4%) samples.

Clinical characteristics of the HBoV-infected children are shown in the Table. Children infected with only HBoV had mild-to-moderate fevers. Leukocyte counts and C-reactive protein levels were normal or moderately elevated. Chest radiographs obtained for 7 children showed abnormalities such as hyperinflation and interstitial infiltrates. Bronchiolitis was the major diagnosis. Dyspnea, respiratory distress, and cough were the most common respiratory symptoms observed. Four (44%) HBoV-infected children were born preterm, which suggests that these children have an increased susceptibility to HBoV-associated diseases. All children

Address for correspondence: Anna Liberek, Department of Paediatrics, Children’s Gastroenterology and Oncology, Medical University, Ul, Nowe Ogrody 1-680-803, Gdansk, Poland; email: tib@amg.gda.pl
recovered and were discharged within 1 to 6 days.

The 3.4% incidence of HBoV observed in our study is similar to that (3.1%) reported by Allander et al. (2). HBoV was the only infectious agent identified in 6 children, which suggests that it was the causative agent of the disease. However, more studies conducted in children with and without respiratory disease as well as in adults and elderly persons are needed to better assess the pathogenic role of HBoV.

This work was supported by a grant from the Programme Hospitalier de Recherche Clinique of the Montpellier University Hospital (AOI 2003).

Vincent Foulongne,* Michel Rodière,* and Michel Segondy*

*Montpellier University Hospital, Montpellier, France

References


---

**Table. Clinical characteristics of children infected with human Bocavirus***

<table>
<thead>
<tr>
<th>Age (mo)</th>
<th>Sex</th>
<th>Copathogen</th>
<th>Fever (°C)</th>
<th>Leukocytes (×10⁹/μL)</th>
<th>CRP (mg/L)</th>
<th>SaO₂ (%)</th>
<th>Underlying condition (wks of pregnancy)</th>
<th>Diagnosis</th>
<th>Symptoms†</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>M</td>
<td>RSV</td>
<td>39.0</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>None</td>
<td>Bronchiolitis</td>
<td>D, C</td>
</tr>
<tr>
<td>39</td>
<td>M</td>
<td>RSV</td>
<td>38.5</td>
<td>14.6</td>
<td>13.0</td>
<td>95</td>
<td>Preterm (36)</td>
<td>Asthma</td>
<td>RD, D</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>RSV</td>
<td>37.5</td>
<td>15.9</td>
<td>13.6</td>
<td>NA</td>
<td>None</td>
<td>Bronchiolitis</td>
<td>RD, C, O</td>
</tr>
<tr>
<td>19</td>
<td>F</td>
<td>None</td>
<td>37.3</td>
<td>15.6</td>
<td>&lt;5.0</td>
<td>91</td>
<td>Preterm (35)</td>
<td>Bronchiolitis</td>
<td>RD</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>None</td>
<td>36.8</td>
<td>NA</td>
<td>NA</td>
<td>95</td>
<td>None</td>
<td>Bronchiolitis</td>
<td>D</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>None</td>
<td>38.2</td>
<td>12.6</td>
<td>9.6</td>
<td>NA</td>
<td>Preterm (28)</td>
<td>Bronchiolitis</td>
<td>D</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>None</td>
<td>38.5</td>
<td>12.7</td>
<td>&lt;5.0</td>
<td>68</td>
<td>Chronic respiratory disease</td>
<td>Acute respiratory distress</td>
<td>RD</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>None</td>
<td>38.1</td>
<td>9.0</td>
<td>38.5</td>
<td>93</td>
<td>None</td>
<td>Bronchiolitis</td>
<td>RD, D, C</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>None</td>
<td>37.8</td>
<td>9.4</td>
<td>&lt;5.0</td>
<td>96</td>
<td>Preterm (31)</td>
<td>Asthma</td>
<td>D</td>
</tr>
</tbody>
</table>

*CRP, C-reactive protein; SaO₂, saturation of arterial oxygen; RSV, respiratory syncytial virus; NA, not available.
†D, dyspnea; C, cough; RD, respiratory distress; O, otitis.

---


Address for correspondence: Vincent Foulongne, Laboratory of Virology, Montpellier University Hospital, 80 Ave A. Fliche, Montpellier 34295, France; email: v-foulongne@chu-montpellier.fr

---

**Extended-spectrum β-Lactamase–producing Enterobacteriaceae, Central African Republic**

To the Editor: Since the early 1980s, extended-spectrum β-lactamases (ESBLs) have been the largest source of resistance to broad-spectrum oximino-cephalosporins among Enterobacteriaceae (1). Molecular analysis techniques suggest that many ESBLs are derived from mutations in TEM-1, TEM-2, and SHV-1 β-lactamases and that these ESBLs can hydrolyze the extended-spectrum cephalosporins (particularly cefotaxime and aztreonam (1)). Members of a new group of ESBLs have been recently identified (1). Among them, CTX-M–type ESBLs are rapidly expanding and are derived from chromosomal class A β-lactamases of *Klebsiella* spp. (1,2). The CTX-M enzymes are not related to TEM or SHV enzymes, as they share only 40% identity with these ESBLs (2). These ESBLs are usually characterized by a higher level of resistance to ceftaxime than ceftazidime, except for CTX-M-19 (2). Most organisms that harbor ESBLs are also resistant to other classes of antimicrobial drugs, such as aminoglycosides, fluoroquinolones, chloramphenicol, and tetracyclines (1,2).

Reports concerning the existence of ESBL-producing Enterobacteriaceae in sub-Saharan Africa are scarce. We therefore conducted a study in the Central African Republic to determine the frequency of ESBLs in *Enterobacteriaceae* isolated at the Institut Pasteur de Bangui and to characterize their *bla*<sub>TEM</sub>, *bla*<sub>SHV</sub>, and *bla*<sub>CTX-M</sub> genes.

From January 2003 to March 2005, all *Enterobacteriaceae* isolated from human specimens at the Institut Pasteur de Bangui were screened for ESBLs. Antimicrobial drug susceptibility was determined by using the disk diffusion method (Bio-Rad, Marnes la Coquette, France) on Mueller-Hinton agar (MHA) and interpreted according to the recommendations of the Comité de l’Antibiogramme de la Société